Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Sponsor: ImmuneOncia Therapeutics Inc.
Summary
This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type
Official title: An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
23
Start Date
2020-10-27
Completion Date
2026-02-28
Last Updated
2025-06-18
Healthy Volunteers
No
Interventions
IMC-001
Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)
Locations (5)
Chonnam National University Hwasun Hospital
Gwangju, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Ulsan University Hospital
Ulsan, South Korea